Table 5.
Liver cancer studies: nonzero estimates
| Gene | D1 | D2 | D3 | D4 |
| 11.3.F.6/noseq/ | −0.019 | −0.048 | −0.020 | −0.015 |
| 11.4.G.9/alcohol dehydrogenase 1C (class I), gamma polypeptide, mRNA | −0.099 | −0.255 | −0.024 | −0.105 |
| 12.2.D.6/noseq/ | −0.080 | 0.126 | 0.013 | −0.056 |
| 15.2.D.10/EST387826 cDNA / | −0.097 | −0.070 | −0.009 | −0.043 |
| 15.4.G.9/podocalyxin-like (PODXL), mRNA / | −0.123 | −0.084 | −0.013 | −0.038 |
| 17.2.B.11/ATPase, H+ transporting, lysosomal 9kD (ATP6H), mRNA | 0.057 | 0.116 | 0.036 | 0.004 |
| 20.3.E.12/nomatch/ | −0.008 | −0.007 | −0.008 | −0.006 |
| 20.4.B.3/nomatch/ | 0.125 | 0.034 | 0.005 | 0.033 |
| 22.2.F.6/noseq/ | 0.009 | 0.049 | 0.004 | 0.011 |
| 3.2.E.10/Human G protein-coupled receptor V28 mRNA, complete cds | −0.008 | −0.007 | −0.004 | −0.005 |
| 3.3.B.11/stromal cell-derived factor 1 (SDF1), mRNA | −0.294 | −0.175 | −0.165 | −0.199 |
| 3.3.B.6/noseq/ | −0.039 | −0.004 | 0.016 | 0.006 |
| 4.1.F.6/noseq/ | 0.067 | 0.043 | 0.006 | 0.014 |
| 4.2.H.5/solute carrier family 22, member 1 (SLC22A1), mRNA | −0.018 | −0.067 | −0.082 | −0.047 |
| 4.3.C.1/noseq/ | −0.230 | −0.087 | −0.042 | −0.027 |
| 4.4.B.9/noseq/ | −0.112 | −0.214 | −0.113 | −0.139 |
| 5.1.A.9/noseq/ | −0.049 | −0.277 | −0.080 | −0.037 |
| 6.3.B.3/noseq/ | 0.169 | 0.189 | 0.043 | 0.033 |
| 7.3.A.5/nomatch/ | −0.054 | −0.085 | −0.050 | −0.044 |
| 7.4.A.5/betaine-homocysteine methyltransferase (BHMT), mRNA | −0.109 | −0.007 | −0.045 | −0.068 |
| 8.2.D.8/RNA helicase-related protein (RNAHP), mRNA | −0.446 | −0.899 | −0.628 | −0.803 |
| 9.3.H.1/chromosome 8 open reading frame 4 (C8orf4), mRNA | −0.013 | −0.004 | −0.021 | −0.005 |